DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript
Source: SeekingAlpha
2025-12-16 22:10:05 ET
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children December 16, 2025 5:00 PM EST...
Read the full article on Seeking Alpha
For further details see:
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript
DBV Technologies S.A.
NASDAQ: DBVT
DBVT Trading
4.81% G/L:
$23.185 Last:
111,765 Volume:
$22.19 Open:
DBVT Latest News
DBVT Stock Data
$801,767,672
33,335,677
74.36%
21
N/A
Biotechnology & Life Sciences
Healthcare
FR
Chtillon
